Prostate Cancer - Results from #160

Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa. October 4, 2024

Prostate Specific Antigen and Prostate Cancer in Gender Affirming Hormone Therapy for Transgender or Nonbinary Individuals. October 4, 2024

Impact of Baseline Renal Insufficiency on Piflufolastat F-18 Performance and Investigation of Changes in Renal Function Following Piflufolastat F-18 Administration: Results From the OSPREY Trial. October 4, 2024

Prevalence and Factors Associated With Prostate Cancer Among Transgender Women. October 4, 2024

Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases. October 4, 2024

Pathological Assessment of Men with Grade Group 2 Prostate Cancer. October 3, 2024

Genomic Landscape in Prostate Cancer in a Latin American Population. October 3, 2024

Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. October 3, 2024

Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor. October 3, 2024

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). October 3, 2024

Clarity’s COBRA Study Selected as a Top-Rated Oral Presentation at Prestigious Industry Annual Meeting October 2, 2024

Testosterone Therapy in Men After Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer. October 2, 2024

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. October 2, 2024

Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer. October 2, 2024

Novel intraprostatic MR-guided implantation of multidrug-eluting microdevice for testing of systemic therapy agents in situ; Proof of concept in intermediate- and high-risk prostate cancer. October 2, 2024

When is prostate cancer really cancer? October 2, 2024

CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) October 1, 2024

Partial prostatectomy for localized prostate cancer. October 1, 2024

Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study. October 1, 2024

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). October 1, 2024

Page 9 of 1436